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Purpose/Objective: This study explores the results, in term 
of Local Control (LC) and Disease Free Survival (DFS), of SBRT 
used to eradicate nodal recurrence of prostate cancer 
assessed by Choline-PET scan. 
Materials and Methods: 103 patients with biochemical 
relapse were examined by Choline-PET scan to select those 
with recurrences limited to nodal sites. A total number of 40 
patients were selected and treated with ablative SBRT. 
Among these 7 patients were previously treated for primary 
tumor with surgery, 11 with radiotherapy and 22 with both. 
Median age was 65 years (range 46-85). SBRT was delivered 
by 6 MV Linac (Elekta Synergy), using dynamic micromultileaf 
collimator and intensity-modulated arc therapy optimization. 
During the follow-up the patients were submitted to Choline-
PET scan, Computed Tomography and PSA dosage sixty days 
after treatment and then every 4 month.  
Results: Median follow-up was 57 months (range 3-127). At 
the time of analysis 25/40 (62.5%) patients were still alive, 
13/40 (32.5%) were dead and 2/40 (5%) were lost in follow-
up. Median PSA was 1.04 ng/ml (range 0.1-77.6) in patients 
with Choline-PET negative and 5.65 ng/ml (range 0.37-181.6) 
with Choline-PET positive scan (p<0.05). Among treated 
patients 15/40 were with no evidence disease (NED) at the 
last follow up while 25/40 relapsed out of treated field (4 pts 
in bone and 6 in lymph nodes other then treated). Disease 
Free Survival, Overall Survival and Local Control rates at 2 
and 5 years were 50%, 92% and 90%, and 17%, 56.3% and 90%, 
respectively. Any severe acute or late GI and/or GU toxicity 
(≥G3) was not observed but only mild GI late toxicity in 15% 
of patients. 
Conclusions: Our results confirmed that SBRT for isolated 
nodal relapses from prostate cancer is effective ablative 
treatment with high LC probability rates and is well tolerated 
also. Based on results regarding the survival and disease 
progression SBRT could be considered as a possible 
alternative treatment able to preserve and/or postpone the 
systemic treatments or androgen deprivation therapy in 
patients with isolated relapse of disease. Choline-PET scan is 
useful diagnostic option in order to detect both disease 
progression to lymph-node sites and to evaluate the results of 
SBRT.  
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Purpose/Objective: To analyse if Image guided Radiotherapy 
(IGRT), made on prostate cancer patients treated with 
Simultaneous Integrated Boost technique, could help to 
personalise treatment. 
Materials and Methods: A prospective study was performed 
enrolling prostate cancer patients. Radiotherapy was 
performed for the majority of patients with volumetric Arc 
Therapy technique. The Clinical Target Volume, irradiated by 
SIB-IMRT, included. During CTV delineation procedure each 
patient was planned twice: the first time using a standard 
CTV to PTV enlargement procedure with margins common to 
all patients Afterwards patients started treatment and during 
first week therapy they underwent 5 daily Cone Beam CT 
(CBCT) scanning before dose delivery. Subsequently the 
CBCTs were registered with the simulation CT, hence 
allowing the overall movements evaluation both for organ 
motion and set-up movements at the same time. A new CTV-
IGRT contour was defined by merging all the positions of the 
prostate and SVs; finally 3 mm of margins in all directions 
were added to obtain an individualized IGRT based PTV. The 
sizes of PTVs in both phases of the treatment were 
compared. We used for statistical analysis the Mann Whitney 
Test rank sum test with continuity correction. 
Results: A total of 123 patients were included in the study 
and had a total of 1253 CBCT scans, corresponding a median 
of 10 CT scans (range 0-27) for each patient.  
To 98 patients a total dose of 80 Gy was prescribed on CTV1 
(prostate) (mean dose 79,5- range 56-80; only three patients 
did not receive prescribed dose for other reasons) delivered 
in 40 fractions within a median of 58 days (range 32-127); 
CTV2 received a total dose of 72 Gy fractionated into 1.8 
Gy/die. In 15 high risks patients CTV1 (prostate and base or 
whole seminal vesicles, depending on the stage) received a 
total dose of 67,5 Gy fractionated into 2,7 Gy/die and CTV2 
(Pelvic Lymphnodes) received a total dose of 45 Gy 
fractionated into 1,8 Gy/die. 
Median Follow-Up time was 20,4 months (IC 16,8-24,1). 
All patients are still alive at last observations, except for one 
dead for other causes. 
Mean PTV1 (prostate) was 139,94 cm3. Mean PTV1 replanning 
(PTV1r) was 118,66 cm3. Difference between PTV1 vs PTV1r 
was statistically significant (p-value = 0.000882).  
Mean PTV2 (seminal vesicles) was 192,22 cm3. Mean PTV2 
replanning (PTV2r) was 162,42 cm3. Difference between PTV2 
and PTV2r was also statistically significant (p-value = 
0.000723).  
Mean PTV3 (pelvic lymphnodes) was 326 cm3. Mean PTV3 
replanning (PTV3r) was 245 cm3. Difference between PTV3 
and PTV3r was also statistically significant (p-value = 
0.002122). 
Toxicity were in accord with literature. 
Conclusions: IGRT is an efficacious method to obtain a 
personalised treatment whilst maintaining high delivered 
treatment doses. 
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Purpose/Objective: Elaborate predictive model is the new 
challenge to personalize treatment on a single patient. 
Radiobiological models describe effects of radiation 
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treatment on cancer and healthy cells, and these effects are 
generally characterized by tumor control probability (TCP) 
and normal tissue complication probability (NTCP). 
Nowadays, many attempts to create toxicities models have 
been made, simply measuring the 3D dose distribution on 
organ at risks by equivalent uniform dose (EUD) or mean 
dose. Advances in computing and the availability of many 
Machine Learning algorithms allow to catch complex 
interactions between dose and non-dose factors. Aim of this 
study was to test an 'in house software' to elaborate 
predictive model on prostate cancer patients treated in 
exclusive setting. 
Materials and Methods: A prospective study was performed 
on prostate cancer patients, treated with volumetric Arc 
Therapy radiotherapy and Image guided radiotherapy 
technique. We delivered moderate hypofractionation with a 
simultaneous integrated boost (SIB). Clinical Target Volume 
(CTV) included: prostate (CTV1, 80 Gy) and seminal vesicles 
(CTV2, 72 Gy) in the largest part of sample. Cumulative dose-
volume histograms (DVHs) of calculated treatment plans were 
exported from the Eclipse TPS. Data were analyzed by a 
software package, written in R and internally developed, 
called MODDICOM. By specific functions created ad hoc, we 
analysed the impact of Vdose for gastrointestinal and 
genitourinary toxicity, both acute and late (using RTOG and 
CTCAE 4.0 scales). Dose from treatment planning and 
simulated delivery was evaluated to calculate the Niemierko's 
EUD-based NTCP and TCP values. To calculate the EUD-based 
NTCP, we used parameterizations of the dose-response 
characteristics using Lyman NTCP formula.  
Results:
A total of 123 patients were recruited. Using MODDICOM we 
found a significant correlation (Mann-Whitney Test p=0,054, 
Logistic Model p=0.00692, Cox Model p=0.0198) between a 
Vdose of 59,5 Gy and late rectal toxicity probability of Grade 
1, in terms of proctitis and rectal haemorrhage from CTCAE 
4.0. This result agrees with the literature, in particular with 
QUANTEC revision of constraints for Radiotherapy. Moreover, 
toxicity and rectal EUD significantly correlate (p=0.06827). A 
EUD based DVH-reduction method, was used by MODDICOM to 
compute NTCP. Our patients were distributed on or close to 
an S slope showing that 50% probability of late G1 rectal 
toxicity is present with a mean delivered uniform dose of 
66,5 Gy.  
Conclusions: MODDICOM, tested on this setting of patients, 
showed good proof of reliable, providing results according 
with the common criteria used to validate Radiation 
Treatment plans. The development of this software could 
help clinicians to elaborate predictive models, in order to 
analyze patients series for radiobiological modeling purposes.  
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Purpose/Objective: Prostate cancer (PrCa) is the most 
common cancer for men with a ten-years overall survival (OS) 
between 60 and 70%. Radiotherapy, which is one of the main 
treatment for PrCa, is limited by normal tissue toxicity. 
Therefore, a further increase in OS requires a specific 
radiosensitisation of PrCa without further damage to normal 
tissue. It was tested by us whether targeting of repair of DNA 
double-strand breaks can be implemented for a specific 
radiosensitisation.  
Materials and Methods: Previously, we reported a functional 
hierarchy between DSB repair pathways to ensure faithful 
and fast repair. Deregulation of this hierarchy switches the 
repair to an inaccurate repair mode which is PARP1-
dependent (PARP1-EJ). In the current study, we investigated 
the hypothesis that this switch is responsible for PARPi-
mediated radiosensitization in tumor cells. To that end, we 
firstly analyzed the radiosensitization effect of Olaparib on 
15 different tumor cell lines. We characterized cells which 
are radiosensitized (responders) and others which are not.  
Results: By analysing several different tumor cell lines it is 
shown by us that PrCa cell lines often shift to this DSB repair 
mode. As a consequence in this PrCa cell lines DSB repair is 
depressed when PARP1 is knocked down by the specific 
inhibitor olaparib (responders). In contrast, no reduction in 
DSB repair was seen in cells still using the classical NHEJ 
(non-responders). In responders inhibition of PARP1 by 
olaparib also results in a drastic radiosensitisation, which was 
not seen for non-responding tumor cells and likewise not for 
normal cells. It was also shown by us that this shift to PARP1-
EJ results from defect in Ku-binding, which is the initial step 
of NHEJ. Biomarkers are now tested which can be used to 
detect PrCa shifted to PARP-EJ in order to identify patients 
which might be treated by RT in combination with PARP1 
inhibition. 
Conclusions: Overall our data indicate that in PrCa where 
DSB is shifted to the PARP1 dependent EJ a specific 
radiosensitisation is achieved by the PARP1 inhibitor olaparib 
without further increase in normal tissue toxicity. 
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